Day 2

Gain insight into today’s sessions so you can get the most out of your conference experience.

Valuable insights can be drawn from international examples of navigating market access. Understand different international pricing models, regulatory landscapes, and reimbursement strategies, along with recommendations. Master the success factors to:

• Compare key approaches to market access with a view to identifying best practices applicable to the Canadian landscape.
• Explore international market access pathways and supporting projects.
• Learn how global regulatory trends and policy shifts impact Canadian market access and which proactive strategies can be implemented for long-term success.

Perfect a future-proof approach to market access with insights from beyond Canada’s borders.

Ensuring robust pharmaceutical supply chains is essential for maintaining consistent drug availability and safeguarding public health. Develop key strategies to enhance your supply chain resilience. Source your plan of action by:

• Diversifying manufacturing and sourcing, including shifting towards options such as local production.
• Enhancing supply chain visibility and transparency.
• Evaluating policy and guidance on supply and stockpiling.

Impact key challenges facing the supply chain to enhance resilience, streamline operations, and ensure consistent drug availability.

AI and big data are revolutionizing market access by streamlining regulatory processes, optimizing pricing strategies, and accelerating approvals. Adopt best practices to:

• Explore how AI-driven analytics and predictive modelling can support faster regulatory approvals and reimbursement decisions.
• Understand the role of big data in demonstrating real-world evidence and health outcomes to strengthen market access strategies.
• Learn how pharmaceutical companies and policymakers can integrate AI and data-driven insights to enhance pricing negotiations, optimize formulary decisions, and improve healthcare sustainability.

Amplify the latest technologies to enhance decision-making and improve patient access to innovative treatments.

With the rise of cell and gene therapies, which have high upfront costs, payers need long-term efficacy data to justify investments. Build credibility with patients and payers. Achieve a step-by-step action plan to:

• Use RWE to monitor durability of response, relapse rates, and cost-effectiveness over time, ensuring pricing reflects the therapy’s sustained value.
• Explore a subscription-based or annuity payment model for higher-priced therapies.
• Engage with HTA bodies and payers early to co-develop evidence expectations and value frameworks tailored to novel therapies.

Bolster trust, support adherence, and amplify real-world outcomes that reinforce higher cost therapy value.

Hear directly from patient advocacy groups on why improving access and research into orphan drugs is vital for patients with rare diseases. Develop a blueprint to:

• Streamline research and development through coordinated stakeholder efforts with patients in mind.
• Use flexible access models that are outcome-based to promote early access for rare disease patients.
• Understand the impact of advocacy to leverage patient groups to shape policy and drive access.

Achieve the needs of patients with rare diseases in your market access strategies to ensure timely, equitable access to innovative treatments and improve patient outcomes.

The federal government has committed $1.5 billion over three years to help provinces and territories cover the costs of high-priced rare disease treatments. Implementing the National Strategy for Drugs for Rare Diseases requires ongoing collaboration, transparency, and adaptability among all stakeholders. Walk away with an action plan on:

• Understanding the challenges still faced by patients across Canada on receiving access to the right treatments.
• Assessing the steps towards collaboration made in 2025 at the provincial, federal, and industry level.
• Exploring how this funding has reduced treatment delays, improved patient outcomes, and fostered a more sustainable rare disease drug ecosystem.

Improve coordination of access to treatments for rare disease patients to ensure timely, equitable access to life-saving therapies and enhance overall patient outcomes.

The Canadian Association for Health Research (CAHR) and other agencies are actively engaged in several initiatives to enhance drug research and health policy in Canada. Take back to your office strategies to:

• Advocate for more federal funding to support innovative health research and sustained investment in scientific studies to improve public health outcomes.
• Collaborate on research projects between academic institutions, healthcare organizations, and pharma to accelerate the development of new therapies and medical technologies, both nationally and internationally.
• Examine the role of policy in shaping research, data and clinical trials conducted in Canada and how that looks from a global perspective.

Optimize your data and clinical trial initiatives for improved innovation and access.

As digital health and telemedicine reshape the healthcare landscape, forward-thinking organizations are incorporating these tools into their market access plans. Drive access through improved digital integration. Create a roadmap to:

• Expand geographical reach and access through telemedicine to broaden patient access to therapies in underserved or remote areas.
• Strengthen evidence generation through digital health tools and the use of patient data.
• Enhance patient support and adherence through virtual platforms to deliver ongoing support, education, and monitoring.

Transform how digitalization of healthcare can improve market access to patients.

Patient Support Programs (PSPs) play an increasingly vital role in delivering value across the healthcare ecosystem, benefiting payers, manufacturers, and patients alike. Explore strategies to enhance your PSP and drive impact across stakeholder groups. Source practical tips to:

• Increase utilization and patient adherence by expanding and optimizing digital support within your PSP.
• Use PSP-generated data to inform real-world evidence initiatives and guide decision-making for improved outcomes for patients.
• Leverage PSP infrastructure to navigate reimbursement challenges and proactively address access barriers.

Heighten the power of PSPs to support smoother treatment pathways for patients from access to reimbursement.

Explore how Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technologies are reshaping the healthcare landscape and what it takes to secure market access for these high-impact, high-cost innovations.  Master the success factors to:

• Payers requiring clear evidence of long-term safety, durability, and cost-effectiveness to support CRISPR reimbursement.
• Engaging with innovative payment models like outcomes-based or annuity agreements that are critical for affordability and adoption.
• Rolling out early market access planning for data collection and treatment success.

Master how top innovators in the sector are addressing market access challenges to drive the successful adoption of breakthrough treatments and ensure sustainability in the healthcare ecosystem.

Review the key solutions and takeaways from the conference. Source a summary of action points to implement in your work.